Effect on the endocrine system of a new dopaminergic agent, ibopamine.
Ibopamine, an oral dopaminergic and adrenergic agent, was given to 19 healthy men to investigate the effect of this dopamine analogue on carbohydrate metabolism. In a three-part study six subjects received ibopamine alone, seven subjects were pretreated with metoclopramide (a dopamine antagonist), and six subjects received phentolamine (an alpha-receptor antagonist) and propranolol (a beta-receptor antagonist) to study the specific mechanisms involved. In these single-blind, controlled, randomized studies, effects on fasting glucose, insulin, glucagon, and prolactin were evaluated. Ibopamine, 300 mg, produced a statistically significant increase in fasting glucose and insulin levels but had no effect on glucagon or prolactin levels. Pretreatment with metoclopramide or phentolamine did not block these effects, but pretreatment with propranolol significantly (P less than 0.05) blunted the increase in fasting glucose and insulin levels. These findings indicate that, unlike other dopaminergic agonists, administration of ibopamine results in increased glucose levels without affecting glucagon. The effect on glucose is mediated through stimulation of beta-adrenergic receptors.
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D003846:Deoxyepinephrine / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000494:pharmacology; D004298:Dopamine / Q000031:analogs & derivatives*; D005934:Glucagon / Q000097:blood*; D006801:Humans; D007328:Insulin / Q000097:blood*; D008297:Male; D008787:Metoclopramide / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D011388:Prolactin / Q000097:blood*; D011433:Propranolol / Q000494:pharmacology
D001786:Blood Glucose; D007328:Insulin; C023487:ibopamine; D011388:Prolactin; D005934:Glucagon; D011433:Propranolol; D008787:Metoclopramide; D003846:Deoxyepinephrine; D004298:Dopamine; D010646:Phentolamine